Invited Speakers
Invited Speakers
Embedded Files
Dr Ildem Akerman, PhD
Dr Ildem Akerman, PhD
Dr Akerman is a Diabetes UK RD Lawrence Fellow and Senior Lecturer in Functional Genomics. She is answering fundamental questions about gene regulation in diseased and healthy pancreatic beta cells through integrated use of molecular, genomic, computational and systems biology. In particular, her aim is to understand how various types of noncoding DNA elements interact to establish gene expression in the pancreatic beta cell.
Dr Elizabeth Baranowski, MD
Dr Elizabeth Baranowski, MD
Liz is a Medical Research Council Awarded Research Training Fellow within the Institute of Metabolism and Systems Research at the University of Birmingham. Her research to date has been focussed on inborn disorders of steroidogenesis such as Congenital Adrenal Hyperplasia, and the fusion of mass spectrometry methods with machine learning analysis for improved patient testing. She is currently a Sub-Specialty Trainee in Paediatric Endocrinology and Diabetes working at Birmingham Children's Hospital and is also the Academic Representative on the West Midlands Paediatric Trainee Committee. As well as secretary for the EYES 2021 Local Organising Committee she is also a current Early Career member and this year's Lead for the Endocrinology Theme on the Scientific Committee for MSACL (Mass Spectrometry Applications in the Clinical Laboratory).
Professor Jérôme Bertherat, MD, PhD
Professor Jérôme Bertherat, MD, PhD
Jérôme Bertherat is President-Elect of the European Society of Endocrinology (ESE), Professor of Endocrinology at Paris University, Chief of the Endocrinology Department of Cochin Hospital, Head of the National Centre for Rare Adrenal Diseases and of the research team “Genomics and Signaling of Endocrine Tumours” in the Cochin Institute (INSERM), Paris, France. He serves as the coordinator of the French National Network for Rare Endocrine Disorders. He has been dedicated to the international Endocrine Community with positions including: Deputy editor of the European Journal of Endocrinology, a member of the Nominations Committee, Congress Committee, and the Executive Committee of the European Society of Endocrinology. In addition he was Chair of ESE’s Clinical Committee. He has played a founder role in various international research or health care collaborative efforts such as the European Network for the Study of Adrenal Tumours and the ENDO-ERN. He has served in various committees of the Endocrine Society and is an ISE Executive Committee member representing Europe. He is an international research leader on Cushing’s syndrome, the genetics of familial adrenal tumours and the molecular genetics of endocrine tumours. His laboratory has identified major genes involved in adrenocortical tumour formation. He is the author of more than 450 publications with anH-index of 77.
Professor Kristien Boelaert, MD, PhD, MRCP
Professor Kristien Boelaert, MD, PhD, MRCP
Dr Boelaert is a Senior MRC-funded Research Fellow and practising Professor of Endocrinology with lead roles in the Thyroid Services at the UHB NHS Foundation Trust. Her laboratory research interests focus on the pathogenesis of thyroid cancer and in particular on the identification of novel diagnostic and therapeutic approaches for patients with thyroid cancer and goitre. In addition, she has a wide interest in clinical and translational research including the management of thyroid dysfunction and thyroid nodules.
Professor Davide Calebiro MD PhD DSc
Professor Davide Calebiro MD PhD DSc
Professir Calebiro is a Professor of Molecular Endocrinology and Wellcome Trust Senior Research Fellow at the Institute of Metabolism and Systems Research (IMSR) and Co-Director of the Centre of Membrane Proteins and Receptors (COMPARE) of the Universities of Birmingham and Nottingham. He is serving on multiple panels and committees, including the Programme Committee of the Society for Endocrinology and the MRC Molecular & Cellular Medicine Board.
He leads a multidisciplinary research team comprising biologists, chemists, physicists, engineers and computer scientists focusing on the basic mechanisms of G protein-coupled receptor (GPCR) signalling and their alterations in endocrine and metabolic diseases. To study GPCR signalling in cells and tissues, they develop and use innovative optical methods based on FRET and single-molecule microscopy, which allow them to directly observe signalling events in living cells with unprecedented spatiotemporal resolution. His major scientific contributions include the discovery that GPCRs are not only active at the plasma membrane but also at intracellular sites and that these receptors interact among themselves and with other membrane proteins to form dynamic nanodomains at the plasma membrane.
Professor Adrian J L Clark
Professor Adrian J L Clark
Professor Clark is Honorary Professor of Endocrinology at Barts & the London School of Medicine & Dentistry and Chairman of the Board of Bioscientifica. His research has centred around the molecular genetic basis of hormone resistance syndromes and the action of ACTH. After graduating in Medicine from St Bartholomew’s Hospital Medical College, he undertook specialist training in internal medicine and endocrinology. He then spent a period of five years training in molecular biology and receptor biology at the NIH in Bethesda, USA. He returned to Barts & the London in 1991, becoming Professor of Molecular Endocrinology in 1996 and Professor of Medicine in 2001. He was elected a Fellow of the Academy of Medical Sciences in 1999 and was Deputy Director of the William Harvey Research Institute from 2004 – 2012. He became Dean of Research and Enterprise at St George’s University of London in 2012, and Emeritus Professor of Endocrinology at St George’s from 2015. Professor Clark was Editor-in-Chief of the Journal of Endocrinology and the Journal of Molecular Endocrinology until 2015. He is currently Editor-in-Chief of Endocrine Connections and Chair of Bioscientifica.
Dr Laurence Colin
Dr Laurence Colin
Dr Laurence Colin is currently co-coordinator of the LS4 panel (Physiology in Health, Disease and Ageing) at the European Research Council Executive Agency (ERCEA) in Brussels. She holds a PhD in molecular and cellular biology from the Free University of Brussels (2011), during which she worked on the HIV-1 latent reservoirs. She then was an FNRS researcher in the laboratory of Cancer Epigenetics from the Erasme Hospital (Brussels) from 2012 to 2015, where she studied the impact of epigenetics on type II diabetes. She is involved in the ERC Starting Grant and Advanced Grant evaluations for the LS3 and LS4 panels. She is also involved in the ERC Synergy Grant evaluation, which has been relaunched in 2018.
Dr Daniela Cota, MD
Dr Daniela Cota, MD
Daniela Cota obtained her Medical Degree in 1999 at the University of Bologna (Italy), where she also obtained a scholarship in Clinical Endocrinology. From 2001 to 2003, Dr. Cota worked as a research fellow at the Max Planck Institute of Psychiatry, Munich (Germany). From 2004 to 2007, she had a post-doctorate contract at the Institute of Metabolic Diseases of the University of Cincinnati (USA). In 2008, Dr. Cota obtained a research position as independent principal investigator at the French Medical Research Institute (INSERM) and established her own laboratory at the NeuroCentre Magendie in Bordeaux, France. She currently serves as INSERM Research Director and team leader of «Energy Balance and Obesity».
Dr. Cota and her lab study the neural circuits and intracellular signaling cascades that are involved in the regulation of food intake and in the brain-periphery cross-talk relevant for the regulation of whole body metabolic responses. Her work on the endocannabinoid system has fundamentally helped establish the role of this system in the regulation of energy balance and as a therapeutic target in obesity and diabetes. At the same time, her groundbreaking studies on the mTORC1 intracellular pathway were the first to demonstrate that mTORC1 is a critical integrator of the effects of hormones and nutrients on the hypothalamus, one of the main brain's structures controlling energy balance. For further information on Dr. Cota’s work and on her lab, please visit:
Dr Gabriela Da Silva Xavier MEd, PhD, SFHEA
Dr Gabriela Da Silva Xavier MEd, PhD, SFHEA
Gaby is Senior Lecturer in Cellular Metabolism and a Senior Fellow of the Higher Education Academy. She has an interest in energy homeostasis, particularly in fuel sensing mechanisms that may play a role in diabetes and obesity.
Professor Martin Fassnacht, MD
Professor Martin Fassnacht, MD
Martin Fassnacht is member of the ExCo of ESE since May 2021 and chairs the Sciences Committee of ESE. He studied medicine at the universities of Saarbrücken and Würzburg and completed his medical training in Würzburg. In-between he joined the Duke University in North Carolina as postdoctoral fellow for 2 years. In 2012, he was appointed as professor of endocrinology at the University of Munich, and since 2014 he is the successor of Bruno Allolio as Professor of Internal Medicine and Endocrinology and Chair of the Department of Endocrinology and Diabetes at the University Hospital in Würzburg.
Martin served on several boards of national and international endocrine societies including the Clinical Committee of ESE. He has been a founding member, working group head, and chair of the European Network for the Study of Adrenal Tumors (ENSAT). Furthermore, he had been one of the three initiators of the supporting organization for young researchers in endocrinology (YARE), the German predecessor of EYES.
His scientific interests mainly relate to endocrine tumors, adrenal and pituitary diseases, and obesity. He was involved and chaired several internationals collaborative projects funded by national and international funding agencies.
Ms Helen Gregson
Ms Helen Gregson
Helen Gregson has been an Associations professional for over 25 years. She has worked with ESE since its launch as an individual membership society in 2006, and since March 2016 as its Chief Executive Officer. In her role she has responsibility, in partnership with the ESE Executive Committee and the ESE Team, to progress ESE’s development and deliver on its vision and objectives. ESE aims to make a real positive difference to the world of endocrinology, and to support its members and the endocrine community to improve health and treatments through endocrine science. ESE has a base in both the UK and Brussels, and Helen is located in Bristol, UK, with the ESE team operating remotely with team members in UK, Belgium and Poland.
Dr Rowan Hardy, BMedSc, PgC, PhD
Dr Rowan Hardy, BMedSc, PgC, PhD
Dr Hardy is an early career scientist specialising in steroid metabolism, with extensive experience in inflammatory animal models. Having recently received a prestigious Career Development Fellowship he is now establishing a research group focussing on the roles of glucocorticoid signalling in inflammatory disease, examining a role for therapeutic agents that modify glucocorticoid signalling.
Dr Zaki Hassan-Smith, MBBS, BMedSci, MRCP, PhD, FRCP
Dr Zaki Hassan-Smith, MBBS, BMedSci, MRCP, PhD, FRCP
Dr Zaki Hassan-Smith is Consultant Endocrinologist at University Hospitals Birmingham NHS Foundation Trust and an Honorary Senior Research Fellow at the University of Birmingham. He has clinical responsibilities in Endocrinology, Metabolic Bone, Bone Genetics/Transition, Thyroid Disease, Antenatal Endocrine/Thyroid and Internal Medicine. He trained in London and Birmingham, UK. His research interests were developed during National Institute for Health Research (NIHR) ACF, European Research Council (ERC) Clinical Research Fellow & Clinical Lecturer posts.
Professor David J. Hodson BVSc (Hons) PhD FRCVS
Professor David J. Hodson BVSc (Hons) PhD FRCVS
Professor Hodson is Professor of Cellular Metabolism, Professorial Research Fellow and ERC Starting Grant holder. He has particular interest in using multidisciplinary and innovative approaches (e.g. biophotonics, mouse genetics, modelling, chemical biology) to tackle challenging research questions in metabolism. The overall objective of his work is to identify new mechanisms through which pancreatic alpha-, beta- and delta-cells fail during type 1 diabetes and type 2 diabetes.
Dr Marta Koch, PhD
Dr Marta Koch, PhD
Marta Koch began her research career at the Porto Oncology Institute, Portugal, in 2000. She was awarded a doctorate degree in biomedical sciences from The University of Leuven, Belgium, and has pursued postdoctoral studies at the University of Leuven and at The Scripps Research Institute, Florida, USA. Marta has been a professional editor since joining the journal Cell in 2015. Her editorial experience extended through diverse basic science, translational and clinical research topics. She joined the Lancet group in 2018 as the inaugural Editor-in-Chief of EClinicalMedicine. She has been serving the diabetes and endocrinology communities as Editor-in-Chief of The Lancet Diabetes & Endocrinology since early 2019.
Dr Zsombor Koszegi, PhD
Dr Zsombor Koszegi, PhD
Dr Koszegi completed a PhD in neuroscience at the University of Otago in New Zealand with a focus on neuroendocrinology. After that, he worked as a postdoc at Kyoto University in Japan, learning single-molecule microscopy, before moving to the University of Bristol in the UK to work in the field of molecular neuroscience. He currently works at the University of Birmingham with Prof Davide Calebiro studying GPCR signalling.
Dr Ganesh Manjeri, PhD
Dr Ganesh Manjeri, PhD
Ganesh graduated from St. Xavier’s College, Mumbai with a B.Sc. in Zoology and Biochemistry. He moved to UK to pursue his M.Sc. in Cancer cell and Molecular Biology at the University of Leicester. Subsequently, he completed his PhD in Mitochondrial Medicine from Radboud University Medical Centre in Nijmegen, The Netherlands from the labs of Prof. Jan Smeitink and Dr. Peter Willems. Later, he did his postdoctoral fellowship with Prof. Gareth Lavery at the IMSR, University of Birmingham, UK where he investigated the role of Vitamin B3 derivates in skeletal muscle metabolism for healthy aging. Ganesh moved back to India in 2017, to take up the role of a Senior Scientific Writer and Reviewer with Indegene Pvt. Ltd. Currently he works with GlaxoSmithKline as a Senior Scientific Writer, where he facilitates regulatory submissions for vaccine research.
Dr Parth Narendran, FRCP, PhD
Dr Parth Narendran, FRCP, PhD
Parth is a qualified clinician by background. His research is primarily on type 1 diabetes, in particular on how to preserve the function of insulin producing pancreatic beta cells. He is currently the co-lead for the West Midlands Clinical Research Network and was previously the diabetes theme lead for the Birmingham and Black Country Clinical Research Network from 2010-14. He leads the Diabetes Research Unit and the Type 1 Diabetes clinical service at the Queen Elizabeth Hospital. He is the author of over 50 peer-reviewed publications including publications that have been cited by international bodies on Type 1 diabetes and its management. He currently sits on the Diabetes UK Research Committee and was previously on the Research Advisory Board of the Diabetes Research and Wellness Foundation and Regional Advisory Committee for the NIHR RfPB programme. Parth reviews for all the major national and international diabetes journals. He contributes to the NIHR Horizon Scanning, and NICE Medical Technology reviews for new therapies.
Dr Michael O'Reilly, FRCPI, PhD
Dr Michael O'Reilly, FRCPI, PhD
Dr O’Reilly’s research focuses on the metabolic consequences of androgen excess in women, with a focus on adipose tissue dysfunction. He also studies the sexually dimorphic impact of androgens on human metabolic health, looking specifically at the overlapping adverse metabolic phenotype of women with androgen excess and men with androgen deficiency. He has a clinical subspecialist interest in polycystic ovary syndrome, adrenal tumours and endocrine infertility.
Dr John Porter, MBBS, PhD
Dr John Porter, MBBS, PhD
John trained in paediatric endocrinology at Birmingham Children’s Hospital and has a PhD in the genetics of non-type 1 diabetes. John joined the pharmaceutical industry in 2008 and has worked in Pfizer, Novartis and GSK in a number of therapeutic areas ranging from endocrinology to vaccines and haemophilia. John joined Diurnal- a spinout company from University of Sheffield in 2015 and has been part of the team taking the first two products of this company from initial trials through licensing and commercialisation in UK, Europe, US and Australia. John is currently the Chief Medical Officer for Diurnal leading the clinical trials, regulatory, pharmacovigilance and medical affairs strategies for the company.
Dr Jane Reznick, PhD
Dr Jane Reznick, PhD
Jane Reznick completed her PhD at the Garvan Institute in Sydney (Australia) studying the impact of circadian rhythms in energy metabolism. She then moved to Berlin to do a post-doc at the Max Delbrück Centre for Molecular Medicine where she first came across the naked mole-rat, a long-lived mammal achieving lifespans of over 35 years. Jane researched various molecular adaptations in this extraordinary animal with a particular focus on metabolic adaptations under extreme hypoxic conditions. With a background in metabolic diseases, during her post-doc, Jane also discovered a novel protein involved in whole-body glucose homeostasis and is now developing a drug against this novel target for the treatment of Metabolic Syndrome and T2 Diabetes. In July 2020, Jane started her own group at CECAD in Cologne where she continues to research metabolic plasticity in the naked mole-rat with a particular focus on cardiometabolic disease.
Dr Elizabeth Robertson, PhD
Dr Elizabeth Robertson, PhD
Elizabeth is Director of Research and joined Diabetes UK in April 2016. She is responsible for ensuring Diabetes UK is driving forward understanding, diagnosis, prevention and treatment of diabetes, through investing in the best research minds and projects. Before joining Diabetes UK, Elizabeth was the first Director of Research for Breast Cancer Now, formed from the merger of Breakthrough Breast Cancer and Breast Cancer Campaign. Prior to the merger, she was the Director of Research, Policy and Information at Breakthrough Breast Cancer. Previous roles include Director of Operations at Cancer Research UK, Dean of the Graduate Research School at Teesside University and Post-doctoral Research Associate in the Department of Biology at York University. Elizabeth completed her PhD at Queen Mary, University of London and Sloan Masters in Leadership and Strategy from London Business School. She is a Trustee of the Association of Medical Research Charities, the Quadram Institute Bioscience, King’s College Hospital Charity and a former Trustee of the national volunteering charity, TimeBank.
Dr Cristina Ronchi, MD, PhD
Dr Cristina Ronchi, MD, PhD
Cristina Ronchi is an Endocrinologist and clinician scientist with long-standing expertise in endocrine tumors. Her research field mostly focuses on genetic studies and investigations of molecular markers involved in the pathogenesis and prognosis of adrenocortical neoplasia. She is particularly active in research dissemination and collaborates with several world-leading groups around Europe. Clinically active as a Consultant in Endocrinology, she actively participates in clinical trials. Dr Ronchi is regularly involved in teaching undergraduate and postgraduate students at the School of Medicine.
Dr Vicki E. Smith PhD
Dr Vicki E. Smith PhD
Vicki is a Lecturer in Molecular Endocrinology in the Institute of Metabolism and Systems Research at the University of Birmingham. Her current research interests are focussed on enhancing radioiodine uptake in thyroid and breast cancer and investigating the molecular pathogenesis of thyroid disease, particularly the signalling pathways that contribute to thyroid cancer growth and progression.
Vicki has authored a number of publications and has presented data at both national and international conferences on Endocrinology and Thyroidology. Her research has attracted funding from the MRC, Wellcome Trust, British Thyroid Foundation and Society for Endocrinology, and she has won a number of awards including the Society for Endocrinology Young Endocrinologist Prize Lecture and the Journal of Molecular Endocrinology Prize.
Prof Karl-Heinz Storbeck, PhD
Prof Karl-Heinz Storbeck, PhD
Karl Storbeck is an Associate Professor in Biochemistry at Stellenbosch University, South Africa and an honorary senior research fellow at the Institute of Metabolism and Systems Research at the University of Birmingham, UK. His research focusses on understanding the role of the overlooked adrenal 11-oxygenated androgens in health and disease. His group has shown that 11-ketotestosterone and 11-ketodihydrotestosterone are bone fide androgens and together with others has implicated 11-oxygenated androgens as important role players in disease states including castration resistant prostate cancer, polycystic ovary syndrome and congenital adrenal hyperplasia. He is an associate editor for the Journal of Steroid Biochemistry and Molecular Biology.
Dr Abd Tahrani, MD, MMedSci, PhD, SCOPE, FRCP
Dr Abd Tahrani, MD, MMedSci, PhD, SCOPE, FRCP
Abd Tahrani is a Senior Lecturer in Metabolic Endocrinology and Obesity Medicine at the University of Birmingham, and a Honorary Consultant Endocrinologist and Bariatric Physician and the lead for weight management research and diabetic neuropathy services at the University Hospitals Birmingham NHS Foundation Trust. Dr Tahrani is also the translational research lead at the Centre of Endocrinology, Diabetes and Metabolism, Birmingham Health Partners and the communication co-lead at the Institute of Metabolism and Systems Research.
In addition, Dr. Tahrani has several national roles including: A trustee of the Association for the Study of Obesity (ASO) UK, the co-chair of the clinical practice and obesity management committee of the ASO UK, a member of the strategic council of the Obesity All Party Parliamentary Group (Obesity APPG), a member of the research committee of the British Sleep Society, an Expert and Clinical advisor to the National Institute for Health and Care Excellence (NICE), and a member of the National Institute for Health Research (NIHR) Research for Patients Benefit (RfPB) and the NIHR Dissemination Centre.
Page updated
Google Sites
Report abuse